Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect

Ken A. Witt, Jason D. Huber, Richard D. Egleton, Thomas P Davis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Insulin crosses the blood-brain barrier (BBB) via receptor-mediated transcytosis and has been suggested to augment uptake of peripheral substances across the BBB. The δ-opioid receptor-selective peptide D-penicillamine2,5 (DPDPE), a Met-enkephalin analog, produces analgesia via a central nervous system-derived effect. In vitro (K(cell), μ1·min-1·mg-1) and in situ (K(in), μl · min-1 · g-1) analyses of DPDPE transport (K(cell) = 0.56 ± 0.15; K(in) = 0.28 ± 0.03) revealed significant (P < .01) increases in DPDPE uptake by the BBB with 10 μM insulin (K(cell) = 1.61 ± 0.25; K(in) = 0.48 ± 0.04). In vitro cellular uptake was significantly increased (P < .05) at 1 μM insulin, whereas no significant uptake was observed with CTAP (a somatostatin opioid peptide analog) or sucrose (a paracellular diffusionary marker). No significant change in uptake was seen with DPDPE, CTAP, or sucrose in the presence of holo-transferrin (0-100 μM), indicating that the effect of insulin on DPDPE was not a generalized effect of receptor endocytosis. Insulin did not affect P-glycoprotein efflux, a mechanism that has shown affinity for DPDPE. A similar uptake of DPDPE into the brain (64% increase) was seen with the in situ brain perfusion model. Analgesic assessment revealed a significant decline in DPDPE (i.v.)-induced analgesia with increasing concentrations of insulin (i.v., i.c.v., s.c.) in a dose-dependent manner. Thus, insulin significantly increases DPDPE uptake across the BBB by a specific mechanism. The analgesic effect seen with DPDPE and insulin coadministration was shown to decrease, indicating that insulin reduces the analgesic effect within the central nervous system rather than at the BBB.

Original languageEnglish (US)
Pages (from-to)972-978
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume295
Issue number3
StatePublished - 2000

Fingerprint

D-Penicillamine (2,5)-Enkephalin
Opioid Peptides
Blood-Brain Barrier
Analgesics
Insulin
Analgesia
Sucrose
Central Nervous System
Transcytosis
Methionine Enkephalin
Brain
Opioid Receptors
P-Glycoprotein
Transferrin
Endocytosis
Somatostatin
Perfusion

ASJC Scopus subject areas

  • Pharmacology

Cite this

Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect. / Witt, Ken A.; Huber, Jason D.; Egleton, Richard D.; Davis, Thomas P.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 295, No. 3, 2000, p. 972-978.

Research output: Contribution to journalArticle

@article{1766568a93ad4aa8a5ac0d9e48c56992,
title = "Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect",
abstract = "Insulin crosses the blood-brain barrier (BBB) via receptor-mediated transcytosis and has been suggested to augment uptake of peripheral substances across the BBB. The δ-opioid receptor-selective peptide D-penicillamine2,5 (DPDPE), a Met-enkephalin analog, produces analgesia via a central nervous system-derived effect. In vitro (K(cell), μ1·min-1·mg-1) and in situ (K(in), μl · min-1 · g-1) analyses of DPDPE transport (K(cell) = 0.56 ± 0.15; K(in) = 0.28 ± 0.03) revealed significant (P < .01) increases in DPDPE uptake by the BBB with 10 μM insulin (K(cell) = 1.61 ± 0.25; K(in) = 0.48 ± 0.04). In vitro cellular uptake was significantly increased (P < .05) at 1 μM insulin, whereas no significant uptake was observed with CTAP (a somatostatin opioid peptide analog) or sucrose (a paracellular diffusionary marker). No significant change in uptake was seen with DPDPE, CTAP, or sucrose in the presence of holo-transferrin (0-100 μM), indicating that the effect of insulin on DPDPE was not a generalized effect of receptor endocytosis. Insulin did not affect P-glycoprotein efflux, a mechanism that has shown affinity for DPDPE. A similar uptake of DPDPE into the brain (64{\%} increase) was seen with the in situ brain perfusion model. Analgesic assessment revealed a significant decline in DPDPE (i.v.)-induced analgesia with increasing concentrations of insulin (i.v., i.c.v., s.c.) in a dose-dependent manner. Thus, insulin significantly increases DPDPE uptake across the BBB by a specific mechanism. The analgesic effect seen with DPDPE and insulin coadministration was shown to decrease, indicating that insulin reduces the analgesic effect within the central nervous system rather than at the BBB.",
author = "Witt, {Ken A.} and Huber, {Jason D.} and Egleton, {Richard D.} and Davis, {Thomas P}",
year = "2000",
language = "English (US)",
volume = "295",
pages = "972--978",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect

AU - Witt, Ken A.

AU - Huber, Jason D.

AU - Egleton, Richard D.

AU - Davis, Thomas P

PY - 2000

Y1 - 2000

N2 - Insulin crosses the blood-brain barrier (BBB) via receptor-mediated transcytosis and has been suggested to augment uptake of peripheral substances across the BBB. The δ-opioid receptor-selective peptide D-penicillamine2,5 (DPDPE), a Met-enkephalin analog, produces analgesia via a central nervous system-derived effect. In vitro (K(cell), μ1·min-1·mg-1) and in situ (K(in), μl · min-1 · g-1) analyses of DPDPE transport (K(cell) = 0.56 ± 0.15; K(in) = 0.28 ± 0.03) revealed significant (P < .01) increases in DPDPE uptake by the BBB with 10 μM insulin (K(cell) = 1.61 ± 0.25; K(in) = 0.48 ± 0.04). In vitro cellular uptake was significantly increased (P < .05) at 1 μM insulin, whereas no significant uptake was observed with CTAP (a somatostatin opioid peptide analog) or sucrose (a paracellular diffusionary marker). No significant change in uptake was seen with DPDPE, CTAP, or sucrose in the presence of holo-transferrin (0-100 μM), indicating that the effect of insulin on DPDPE was not a generalized effect of receptor endocytosis. Insulin did not affect P-glycoprotein efflux, a mechanism that has shown affinity for DPDPE. A similar uptake of DPDPE into the brain (64% increase) was seen with the in situ brain perfusion model. Analgesic assessment revealed a significant decline in DPDPE (i.v.)-induced analgesia with increasing concentrations of insulin (i.v., i.c.v., s.c.) in a dose-dependent manner. Thus, insulin significantly increases DPDPE uptake across the BBB by a specific mechanism. The analgesic effect seen with DPDPE and insulin coadministration was shown to decrease, indicating that insulin reduces the analgesic effect within the central nervous system rather than at the BBB.

AB - Insulin crosses the blood-brain barrier (BBB) via receptor-mediated transcytosis and has been suggested to augment uptake of peripheral substances across the BBB. The δ-opioid receptor-selective peptide D-penicillamine2,5 (DPDPE), a Met-enkephalin analog, produces analgesia via a central nervous system-derived effect. In vitro (K(cell), μ1·min-1·mg-1) and in situ (K(in), μl · min-1 · g-1) analyses of DPDPE transport (K(cell) = 0.56 ± 0.15; K(in) = 0.28 ± 0.03) revealed significant (P < .01) increases in DPDPE uptake by the BBB with 10 μM insulin (K(cell) = 1.61 ± 0.25; K(in) = 0.48 ± 0.04). In vitro cellular uptake was significantly increased (P < .05) at 1 μM insulin, whereas no significant uptake was observed with CTAP (a somatostatin opioid peptide analog) or sucrose (a paracellular diffusionary marker). No significant change in uptake was seen with DPDPE, CTAP, or sucrose in the presence of holo-transferrin (0-100 μM), indicating that the effect of insulin on DPDPE was not a generalized effect of receptor endocytosis. Insulin did not affect P-glycoprotein efflux, a mechanism that has shown affinity for DPDPE. A similar uptake of DPDPE into the brain (64% increase) was seen with the in situ brain perfusion model. Analgesic assessment revealed a significant decline in DPDPE (i.v.)-induced analgesia with increasing concentrations of insulin (i.v., i.c.v., s.c.) in a dose-dependent manner. Thus, insulin significantly increases DPDPE uptake across the BBB by a specific mechanism. The analgesic effect seen with DPDPE and insulin coadministration was shown to decrease, indicating that insulin reduces the analgesic effect within the central nervous system rather than at the BBB.

UR - http://www.scopus.com/inward/record.url?scp=0033711475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033711475&partnerID=8YFLogxK

M3 - Article

C2 - 11082431

AN - SCOPUS:0033711475

VL - 295

SP - 972

EP - 978

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -